Preventing cervical cancer: New vaccine against HPV infections imminent
- Date:
- October 2, 2014
- Source:
- Medical University of Vienna
- Summary:
- Nine sub-types of the human papillomavirus are responsible for 85 per cent of pre-cancerous cells of the cervix. A new vaccine could now prevent these conditions altogether, experts say. It offers a broader spectrum of effectiveness than the vaccines currently available and targets precisely these nine dangerous sub-types.
- Share:
Nine sub-types of the human papillomavirus are responsible for 85 per cent of pre-cancerous cells of the cervix. A new vaccine being tested at the University Department of Gynaecology at the MedUni Vienna could now prevent these conditions altogether. It offers a broader spectrum of effectiveness than the vaccines currently available and targets precisely these nine dangerous sub-types.
Human papillomaviruses (HPV) infect epithelial cells in the skin and mucosal tissue and can cause tumor-like growth. Some of these viruses also develop malignant tumors, especially cervical cancer in women. Men too can develop cancer caused by HPV infections, however. Over a hundred HPV sub-types have been identified.
"We've investigated how much these 9 sub-types account for the direct pre-cancerous stages of cervical cancer," explains Elmar Joura from the University Department of Gynaecology at the MedUni Vienna. "In the case of multiple infections, which account for around 30%, we've investigated what strains the disease can be attributed to. Around 85 per cent of cervical cancer cases are triggered by these nine sub-types."
The high effectiveness of this vaccine has already been demonstrated in a clinical phase III study, for which the MedUni Vienna was an important study centre.
If vaccination programmes are implemented comprehensively with this type of vaccine, the majority of the infections, surgery required and as a result the development of cancer can be prevented. The vaccines that have already been licensed and which are currently used offer excellent effectiveness too. "Despite the high effectiveness and tolerability of HPV vaccines, the complete vaccination rate in Austria is still a long way from being adequate," says Elmar Joura. The implementation of the HPV vaccine in the childhood vaccinations programme this year and the start of the free school vaccinations campaign starting this academic year is intended to help change this situation.
Story Source:
Materials provided by Medical University of Vienna. Note: Content may be edited for style and length.
Journal Reference:
- E. A. Joura, K. A. Ault, F. X. Bosch, D. Brown, J. Cuzick, D. Ferris, S. M. Garland, A. R. Giuliano, M. Hernandez-Avila, W. Huh, O.-E. Iversen, S. K. Kjaer, J. Luna, D. Miller, J. Monsonego, N. Munoz, E. Myers, J. Paavonen, P. Pitisuttithum, M. Steben, C. M. Wheeler, G. Perez, A. Saah, A. Luxembourg, H. L. Sings, C. Velicer. Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. Cancer Epidemiology Biomarkers & Prevention, 2014; 23 (10): 1997 DOI: 10.1158/1055-9965.EPI-14-0410
Cite This Page: